一跨国药企巨头中国三高管同时离任

新康界12-12

据行业媒体消息，安进于12月11日宣布了多项中国区核心高管层人事变动，包括安进副总裁兼中国总经理许蔼龄、安进中国心血管事业部负责人吴海、安进中国骨科业务负责人范成敏同时离任。安进亚太区总经理柯美玲通过邮件向全体员工通报了上述消息，并对三位离任高管过去对公司做出的贡献表示了感谢。据悉，目前安进已启动内外部招聘以尽快确定继任者人选，在找到新的继任者前，柯美玲将兼任安进中国区临时总经理一职，领导中国区...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2490753801?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-12 19:26","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2490753801","market":"us","top_or_hot":-1,"title":"一跨国药企巨头中国三高管同时离任","media":"新康界","content":"<div>\n<p>据行业媒体消息，安进于12月11日宣布了多项中国区核心高管层人事变动，包括安进副总裁兼中国总经理许蔼龄、安进中国心血管事业部负责人吴海、安进中国骨科业务负责人范成敏同时离任。安进亚太区总经理柯美玲通过邮件向全体员工通报了上述消息，并对三位离任高管过去对公司做出的贡献表示了感谢。据悉，目前安进已启动内外部招聘以尽快确定继任者人选，在找到新的继任者前，柯美玲将兼任安进中国区临时总经理一职，领导中国区...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212193546ab724dcd&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>一跨国药企巨头中国三高管同时离任</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n一跨国药企巨头中国三高管同时离任\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 19:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212193546ab724dcd&s=b><strong>新康界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>据行业媒体消息，安进于12月11日宣布了多项中国区核心高管层人事变动，包括安进副总裁兼中国总经理许蔼龄、安进中国心血管事业部负责人吴海、安进中国骨科业务负责人范成敏同时离任。安进亚太区总经理柯美玲通过邮件向全体员工通报了上述消息，并对三位离任高管过去对公司做出的贡献表示了感谢。据悉，目前安进已启动内外部招聘以尽快确定继任者人选，在找到新的继任者前，柯美玲将兼任安进中国区临时总经理一职，领导中国区...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212193546ab724dcd&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212193546ab724dcd&s=b","article_id":"2490753801","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212193546ab724dcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2490753801","pubTimestamp":1734002781,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据行业媒体消息，安进于12月11日宣布了多项中国区核心高管层人事变动，包括安进副总裁兼中国总经理许蔼龄、安进中国心血管事业部负责人吴海、安进中国骨科业务负责人范成敏同时离任。安进亚太区总经理柯美玲通过邮件向全体员工通报了上述消息，并对三位离任高管过去对公司做出的贡献表示了感谢。加入安进前，许蔼龄曾先后在杨森、罗氏等跨国药企的多个区域市场等担任领导职务。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","BK4588":"碎股","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4581":"高盛持仓","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4599":"减肥药","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","AMGN":"安进","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4139":"生物科技","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4566":"资本集团","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Three senior executives of a multinational pharmaceutical giant China resigned at the same time","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":0.9},"content_text":"据行业媒体消息，安进于12月11日宣布了多项中国区核心高管层人事变动，包括安进副总裁兼中国总经理许蔼龄、安进中国心血管事业部负责人吴海、安进中国骨科业务负责人范成敏同时离任。安进亚太区总经理柯美玲通过邮件向全体员工通报了上述消息，并对三位离任高管过去对公司做出的贡献表示了感谢。据悉，目前安进已启动内外部招聘以尽快确定继任者人选，在找到新的继任者前，柯美玲将兼任安进中国区临时总经理一职，领导中国区业务运营。柯美玲表示，安进在中国的战略重心将保持不变，并希望与和员工共度这段变革期，迎接转型挑战。此次离职的安进副总裁兼中国总经理许蔼龄，于2021年8月19日加入安进，任安进副总裁兼中国总经理，向安进副总裁兼亚太区总经理柯美玲汇报。加入安进前，许蔼龄曾先后在杨森、罗氏等跨国药企的多个区域市场等担任领导职务。曾成功领导了组织转型，打造了高度参与、协作和以客户为中心的高绩效企业文化，加速提升患者的用药可及性并推动构建当地医疗政策环境。过去三年多的时间里，许蔼龄带领团队进一步布局中国市场。安进中国心血管事业部负责人吴海也宣布了离开。吴海加入安进前，担任诺华中国中枢神经疾病领域负责人，在此之前，还曾任职于默沙东、辉瑞等跨国药企。2019年，安进在中国成功上市首款创新产品依洛尤单抗，这也是国内首款获批上市的PCSK9抑制剂。同日离职的另一位高管范成敏是安进中国骨健康事业部负责人。范成敏加入安进前，在罗氏中国台湾地区公司任职，在此之前，还曾任职于阿斯利康和诺华的台湾地区市场，在台湾地区和菲律宾市场有领导多个治疗领域的经验。在骨健康领域，安进的生物制剂普罗力（地舒单抗）于2020年在中国上市。2012年，安进进入中国在上海设立总部，2018年，安进把第一款创新药物送到中国市场。入华10多年间，安进已成功将覆盖心血管疾病、骨健康等多个关键疾病领域的7款创新药引入中国，且其中5款药物已纳入医保。目前安进中国业务已覆盖全国近100个城市。信息整理自：E药经理人、MedTalent医人才","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490753801"}